Assessment of the effectiveness of ethylmethylhydroxypyridine of succinate with alcohol withdrawal

Authors:
YAKUSHEVA E.N., SHULKIN A.V., ABALENIKHINA Y.V.

Place of publication: Psychopharmacology and biological narcology / Vol. 15, No. 1, 2024

Ryazan State Medical University named after Acad. I.P. Pavlova, Ryazan, Russia

ABSTRACT
Background. Alcohol (ethanol) use disorder is a devastating condition characterized by disruption of energy and metabolic processes, as well as activation of free-radical oxidation processes. Therefore, the use of antioxidants, in particular the original Russian drug ethylmethylhydroxypyridine succinate, is pathogenetically justified in the complex therapy of this pathology.
Objective : To study the efficacy of ethylmethylhydroxypyridine succinate administered intravenously, intramuscularly, and intragastrically to male ICR mice in a model of alcohol withdrawal.
Materials and Methods. The study was performed on healthy, pathogen-free male ICR outbred mice aged 9–10 weeks. with an average weight of 25.4 ± 0.2 g. Alcohol dependence in animals was modeled by gradually increasing the ethanol content in the drinking bowl from 1 to 3, 6, 10% every 2 days. Upon reaching
a concentration of 10%, the animals were given 1 bottle of alcohol with 1 bottle of water every other day and 2 bottles of alcohol on the intermediate days. The position of the bottles (left / right) was changed between each session of access to alcohol. After 6 weeks, the 10% alcohol solution was removed from the animals. Administration of ethylmethylhydroxypyridine succinate and saline
(control group) was started twice a day for 7 days. The drug was administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg) and intragastrically (100 and 150 mg/kg).
Results. In the present study, it was established that ethylmethylhydroxypyridine succinate (Mexidol®) when administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg) and intragastrically (100 and 150 mg/kg) twice a day for 7 days in manifestations of alcohol withdrawal in the
ICR mouse model of alcohol dependence, has pronounced pharmacological activity, which is manifested in a decrease in the volume of alcohol consumption, improvement of horizontal and vertical activity in the open field test, improvement of motor coordination, and a decrease in the severity of withdrawal syndrome revealed in the nesting ability test.
Conclusion. Thus, ethylmethylhydroxypyridine succinate when administered intravenously (50 and 100 mg/kg), intramuscularly (50 and 100 mg/kg) and intragastrically (100 and 150 mg/kg) When administered to male mice, ICR exerted a pronounced therapeutic effect in modeling alcohol withdrawal.
Key words: ethylmethylhydroxypyridine succinate; chronic alcohol intoxication; healthy SPF ICR mice.

How to cite
Yakusheva E.N., Shchulkin A.V., Abalenikhina Yu.V. Evaluation of the effectiveness of ethylmethylhydroxypyridine succinate in alcohol withdrawal //
Psychopharmacology
and biological narcology. 2024. Vol. 15, No. 1. pp. 61–68. DOI: https://doi.org/10.17816/phbn625395